<DOC>
	<DOCNO>NCT00074165</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy , carboplatin , cyclophosphamide , etoposide , etoposide phosphate , cytarabine , use different way stop cancer cell divide stop grow die . Osmotic blood-brain barrier disruption use certain drug open blood vessel around brain allow anticancer substance deliver directly brain tumor . Chemoprotective drug sodium thiosulfate may protect normal cell side effect carboplatin-based chemotherapy . Combining rituximab chemotherapy give osmotic blood-brain barrier disruption plus sodium thiosulfate may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine rituximab combination chemotherapy give osmotic blood-brain barrier disruption plus sodium thiosulfate treat patient refractory recurrent primary CNS lymphoma .</brief_summary>
	<brief_title>Treating Patients With Recurrent PCNSL With Carboplatin/BBBD Adding Rituxan To The Treatment Regimen</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy rituximab , carboplatin , cyclophosphamide , etoposide etoposide phosphate cytarabine administer conjunction osmotic blood-brain barrier disruption high-dose sodium thiosulfate , term complete response rate , patient refractory recurrent primary CNS lymphoma . Secondary - Determine overall survival 2-year progression-free survival patient treat regimen . - Determine quality life cognitive function patient treat regimen . - Determine neurotoxicity regimen patient . - Determine percentage patient ototoxicity time treatment regimen . - Determine effect delay administration sodium thiosulfate granulocyte erythrocyte count patient . OUTLINE : This multicenter study . Patients receive rituximab IV day 1 . On day 2 3 , patient receive carboplatin intra-arterially 10 minute , cyclophosphamide IV 10 minute , etoposide etoposide phosphate IV 10 minute conjunction blood-brain barrier disruption . Patients also receive high-dose sodium thiosulfate IV 15 minute administer 4 8 hour carboplatin day 2 3 intraventricular intrathecal cytarabine day 14 . Beginning 48 hour last dose chemotherapy , patient receive filgrastim ( G-CSF ) * subcutaneously ( SC ) daily 7-10 day blood count recover . Treatment repeat every 4 week 12 course . NOTE : * Alternatively , patient may receive single dose pegfilgrastim SC , administer 48 hour completion chemotherapy Patients intraocular lymphoma also receive methotrexate intravitreally twice weekly vitreous clear cell slit lamp exam ; weekly 1 month ; monthly 1 year . Quality life assess baseline , every 3 month treatment , within 30 day final treatment , every 6 month 1 year , annually thereafter . Patients follow monthly 3 month , every 2 month 8 month , every 3 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 11-25 patient accrue study within 7-10 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Sodium thiosulfate</mesh_term>
	<criteria>INCLUSION CRITERIA : Signed informed consent form accordance institutional guideline Histologically cytologically confirm primary CNS lymphoma document brain biopsy cerebrospinal fluid vitrectomy analysis CD20 positive disease Progressive relapse disease completion prior methotrexatebased chemotherapy Aged 18 month 75 year Performance status ECOG 03 OR Karnofsky 30100 % Hematocrit least 25 % ( transfusion epoetin alfa allow ) Absolute granulocyte count least 1,200/mm^3 Platelet count least 100,000/mm^3 OR least low limit normal Bilirubin great 2.0 time upper limit normal Creatinine le 1.8 mg/dL Calculated Creatinine clearance ( CrCl ) least 50 mL/min Adequate cardiac function tolerate general anesthesia Adequate pulmonary function tolerate general anesthesia Available followup 1 year post therapy Fertile patient must use effective contraception minimum 2 month study participation EXCLUSION CRITERIA : Radiographic sign intracranial herniation and/or spinal block HIV positive Systemic lymphoma Positive serum HCG , pregnant lactating Allergy study agent Hepatitis B hepatitis C positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>thrombocytopenia</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>primary central nervous system Hodgkin lymphoma</keyword>
</DOC>